Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Bifidobacterium animalis subsp. lactis GCL2505
- Development stage
- Preclinical
- Lead developer
- Ezaki Glico
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
**Bifidobacterium animalis subsp. lactis GCL2505** is a strain-specific orally administered probiotic live microorganism that has been studied as a microbiome-directed therapy for gastrointestinal health, particularly constipation. Published human data indicate that this strain survives gastrointestinal transit and, notably for a probiotic, proliferates in the intestine, increasing fecal bifidobacterial counts and improving bowel movement frequency in constipated volunteers. Its therapeutic rationale is modulation of the intestinal microbiota rather than a single defined human molecular target. Based on the provided public-source evidence, it is best characterized as a strain-specific probiotic or microbiome therapy rather than a conventional pharmaceutical drug.
- Other names
- B. lactis GCL2505Bifidobacterium animalis subsp. lactis GCL2505
02
Targets
FFAR2
Beyond the preview
Go deeper on Bifidobacterium animalis subsp. lactis GCL2505.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Bifidobacterium animalis subsp. lactis GCL2505.